Are you a medical doctor looking for a challenging career path in a pharmaceutical company? Would you like to be part of highly qualified and ambitious teams in a global setting? Then this is your unique opportunity to apply for a position with 3 job rotations where you can use your medical and scientific knowledge in an inspiring way to create better treatments and care for our patients.
A career opportunity for MD's with 2-5 year's of experience (*)
Offering a broad introduction to the pharmaceutical industry, the PMP aims to develop medical doctors, who have 2-5 years of clinical experience, within various functions where strong medical competencies are needed. Apply here from February 2019. Programme starts September 2019. (*) If you have more than 5 years of experience show you interest for a medical career here.
Explore Novo Nordisk through 3 rotations
The PMP is a two-year programme with five participants accepted onto the programme each year. After successful completion of the programme participants are offered a permanent position within the company. The programme has been the springboard for many medical doctors’ progression to key positions within Novo Nordisk around the world. With a focus on both personal and professional development, and the knowledge and experience you will gain during the time you spend working in three different functions within the company, the PMP could be your first step towards a life-changing career.
“At Novo Nordisk I have the opportunity to work with highly intelligent people who are dedicated to their job. The PMP programme lets me focus on getting a profound understanding of the different parts of the organization and the opportunity to evolve both personally and professionally, but also to use my competencies as a medical doctor to contribute to the varied tasks in every day work.”
(Sarah Eggert, 1st rotation,
“The PMP programme allows me to challenge and strengthen new parts of my medical professionalism, but at the core, my everyday thinking remains the same: “how do I do what is best for the patients””
(Cecilie Heerdegen Jepsen, 1st rotation,
When speaking of biopharmaceuticals we have a leading position within the therapeutic areas of haemostasis management, growth hormone therapy and hormone replacement therapy. We also have a strong research portfolio within obesity.
Novo Nordisk has more than 42,100 employees in 79 countries. Our employees are driven by the common goal of making a difference to patients, healthcare professionals and society. Each and every employee at Novo Nordisk knows that their contribution helps make this difference. Our ethical culture, high standards and commitment to being socially and environmentally responsible attracts a certain type of employee who is ready to change lives for the better.
All rotations will be based at our corporate headquarters in Denmark (Søborg and Bagsværd), but will involve global work teams as well as international business trips. The amount of travelling will vary depending on departments and projects. Applications from all around the world are encouraged. Each year five applicants will be accepted onto the programme.
Rotations will be within the diabetes and obesity areas. During each rotation you will be fully-integrated into the department and will be given specific tasks and projects, with your own responsibilities and goals. You will gain experience in a broad range of areas, such as:
Every PMP doctor will receive support and mentoring from the PMP manager, who takes care of your overall development throughout your time on the programme, and a daily manager, who is responsible for your development during each rotation. To help you reach your goals, the programme will include both professional and personal training.
The programme aims to educate medical doctors in drug development, how the pharmaceutical industry works and career opportunities within the industry. These aims will be addressed by daily on-the-job training through tasks and interaction with experienced colleagues, and a generous individual training programme including a broad variety of internal and external courses.
On successful completion of the programme, a permanent position at Novo Nordisk will be offered to you within one of the three departments in the programme. Your final position depends upon your wishes, feedback from managers and vacancies in the respective departments.
Global Development, where trial protocols and development plans for new potential drug candidates are made and communication with the authorities concerning approval of trials and drugs is conducted.
Global Medical Affairs, where input is given to the clinical development plans and product strategies. Publication planning, medical communication and data presentation are also anchored in the Medical Affairs rotation.
Global Safety, where adverse events are assessed, safety reports are submitted to competent authorities and trial protocols are reviewed.
First of all, we are involved in the preparation phase of trials, where we give input to the trial outline which is a detailed summary of the rationale, objectives and overall design of the trial. We are also involved in the trial execution phase, where we present and share knowledge with doctors and nurses from various international sites where the trials are conducted, provide input regarding trial adherence, and answer any questions the sites may have regarding trial-related medical and safety issues. Upon completion of the trial, we add medical input towards analysis of results and drafting of conclusions.
At the trial initiation and finalisation phase, we provide medical input to health authorities in order for them to either approve the trial design or to approve our products for sale and marketing, respectively. On the side, we are involved in a wide range of academic and scientific settings where we interact with medical experts, and we provide internal input (within the company) regarding the design of clinical trials to be conducted in the development phase of a new product.
We provide medical education and guidance and do so by developing online learning tools and preparing presentations for visiting physicians, affiliates (company departments in other countries), product launch presentations, and internal management presentations.
In this process we focus on how to communicate the data clearly and we provide input to and review slide decks and presentations. Furthermore, we have interactions with global scientific and clinical experts at Advisory board meetings where experts give their unbiased opinion regarding different aspects related to our products, at Investigator Meetings for people involved in running our trials, e.g. doctors and nurses, and at Result Meetings where trial results are presented.
In addition we interact with them at different congresses or symposia (e.g. American Diabetes Association and Global Diabetes Summit). We provide guidance on investigator sponsored studies (ISS) and are part of the publication planning group meetings and hence responsible for abstracts, papers and posters submitted to congresses and journals. In addition we have cross-sectional collaboration where we provide clinical and strategic input as needed e.g. for clinical trials and promotional materials.
This includes preparation of reports, both internal and external (as Authorities request) that aggregate safety information (e.g. adverse reactions to drugs) regarding a specific product (e.g. Insulin Aspart). Our medical competencies are used to analyse, evaluate and conclude on the drug’s safety profile.
We participate in meetings with colleagues from different departments regarding the clinical trials, providing feedback on protocol designs and informed consent forms prior to the initiation of clinical trials. We also attend Investigator Meetings where we inform the investigators participating in our trials about the specifics of the trial prior to its initiation. While the trial is on-going we present and evaluate blinded safety data to the study group (a group of people from different departments who meet at regular intervals regarding the specific trial). In addition we participate and contribute with input for e.g. Safety Committee meetings and meetings with Data Monitoring Committees.
We perform monthly literature surveillance and monitor recently published scientific articles regarding competitors and our products. In the market application process, we are involved in answering requests from authorities and preparing for advisory committees (panel of experts convened by authorities) if needed.
Documented scientific experience is not a prerequisite, but it is an advantage. The programme offers an introduction to the pharmaceutical industry and the applicant should not have prior industry experience.
You must have practical and analytical skills and be capable of working independently, while at the same time being able to excel in a cross-functional, multi-disciplinary team. Moreover, you should be prepared to travel and work in an international arena.
We expect that you are results-oriented, are good at setting priorities, that you have a broad perspective and an open-mind, and are able to challenge the status quo. Lastly, we expect you to have excellent English skills and be proficient in IT.
Apply here from 22 January 2018 until 28 February 2018.
Application process opens 22 January 2018 and ends 28 February 2018
Screening of applications
March 8-15: candidates will be asked to post a video to present themselves
April 6-16: phone interviews
End April: selected candidates will be invited for a full day interview in Copenhagen, Denmark
Face to face interviews
End of May: candidates will be informed of the final decision
Pharmaceutical Medicine Programme starts 1 September 2018.
“If you want to give a fresh start to your career and develop unexplored skills, this programme could be the right answer. You will face daily challenges guided and supported by experienced and talented colleagues in an inspiring and respectful setting.”
Cristina Parrino (Italy), PMP 1st rotation, Global Development, Team 2015
Together with the intensive professional and personal training available during the programme, this places you in a strong position to go on to be a key person within our organisation after successfully completing the pharmaceutical medicine programme.
And here's the proof! Read the stories below to discover how the ex-participants in our Pharmaceutical Medicine Programme have moved onwards and upwards within the organisation. You can also meet the PMP’s currently enrolled in the programme, and get some key insights into the life as an MD in the pharmaceutical industry.
In 2015 the PMP team included Christin, Cristina, Melissa and Ting.
Christin joined the programme after completing internship and a PhD investigating the genetic background of young sudden cardiac death victims. She is now working as a Global Medical Advisor in Medical Affairs, Oral Semaglutide.
Cristina joined the programme after completing her medical training and speciality in Endocrinology in Italy. After successful completion of the programme Cristina decided to return to public health care system.
Melissa graduated from the University of Copenhagen in 2007, followed by some years of clinical experience, obtained a PhD combining oncology and chronobiology in 2014 and right before joining Novo Nordisk worked within the field of Clinical Pharmacology. After finalising the programme, Melissa joined Global Medical Affairs working as Global Medical Advisor in the Degludec/IDegLira team.
Ting graduated from Peking University in 2006 and completed her specialization in Nephrology later on. She joined the programme after completing her PhD within Nephrology and postdoc in Public Health. After the programme, she is now working as an Senior International Medical Manager in Global Development, Insulin & Devices.
In 2014 the PMP team included Marie, Cecilie, Sarah, Bue and Søren.
Marie joined the programme after completing internship and a PhD within neuroscience. After the programme, she now works as an International Medical Manager in Global Development, Obesity.
Cecilie joined the programme after several years of clinical experience within anaesthesiology, and after having completed a two-year research fellowship within inflammation and endotheliopathy at Harvard/MGH. Cecilie now works as a Global Medical Advisor in the Medical Affairs Obesity team.
Sarah has decided to pursue an adventure with her family and will be travelling for the next year to come.
Bue graduated from University of Copenhagen in 2007 and joined the programme with experience from internal medicine, cardiology and emergency medicine and a PhD in Cardiology. Bue now works as a Global Medical Advisor in Global Medical Affairs, IDegLira.
Søren joined the programme after working in the clinic within cardiology where he also obtained his PhD. After the PMP rotations, Søren continued in Global Development as International Medical Manager in Global Development, Semaglutide, Diabetes & Outcomes.
In 2013 the PMP team included Frida, Keval, Salvatore and Bo
Frida joined the programme after having worked in the clinical setting across various specialties and additional research experience. After the programme Frida worked as a Safety Surveillance Specialist in Global Safety and then left Novo Nordisk to pursue a PhD education.
Keval joined the PMP after completing his medical training in the UK. He also holds a PhD in the role of gut hormones in diabetes and obesity. Keval worked in global medical affairs as a Global Medical Advisor in the IDegLira team and then has become Manager in Medical Affairs in the Canadian affiliate based in Toronto.
Keval joined the PMP after completing his medical training in the UK. He also holds a PhD in the role of gut hormones in diabetes and obesity. Keval now works in medical affairs as a Global Medical Advisor in the IDegLira team.
Salvatore joined the programme after completion of internal medicine residency He embarked on several years of research activities, mainly in pre-diabetes and type 2 diabetes, and completed his PhD at the University of Copenhagen. He now works as a Global Medical Advisor in Global Medical Affairs, and he is also the manager of the PMP.
Bo joined the programme after having specialised as a cardiac electrophysiologist and several years of research, including a PhD within cardiac arrhythmias. Bo now works in Global Development, M&S, Insulin & Digital Health as an International Medical Manager.
In 2012 the PMP team included Ditte, Veronica and Henrik.
Ditte joined the programme after obtaining a PhD within cardiology. She worked as an International Medical Manager in Global Development, M&S, Insulin & Digital Health and after a couple of years decided to continue her career within another pharmaceutical company.
Veronica, who prior to joining the programme worked in the clinic, conducted research, and obtained her PhD within insulin resistance and obesity. Veronica worked as a Safety Surveillance Specialist in Global Safety and after a couple of years left Novo Nordisk to work in another pharmaceutical company.
Henrik Jarlov joined the programme after several years in the clinic working with orthopaedic surgery. He now works as a Global Medical Director in Global Medical Affairs Faster Aspart.
Henrik worked and researched within rheumatology before joining the programme. He chose to return to the public health care system after a year in the programme.
In 2011 the PMP team included Anne K, Anne Ø and Anders.
Anne K joined the program after internship and several years of research and a PhD within type 1 diabetes. After the PMP Anne worked asa Safety Surveillance Specialist in Global Safety for 2 years, before she joined Global Development as an International Medical Director. In addition, Anne was the manager of the PMP programme for 2 years.
Anne Ø finished her internship prior to joining the programme and holds a bachelor degree within Business Administration. Anne now works as an International Medical Manager in Global Development, M&S, Insulin & Digital Health.
Anders Hvelplund, who prior to joining the programme worked in the clinic, conducted research, and completed his PhD within cardiology. After the PMP rotations, Anders continued in Global Development as Medical Specialist in the cardiovascular outcomes group working on the large cardiovascular outcomes trials DEVOTE and LEADER. He was appointed Medical Director in Medical & Science Semaglutide sc. and he is now working in Novo Nordisk Inc. (USA) as Executive Director Clinical Development, Diabetes & Obesity.
In 2010 the team included Ida, Anders and Florian.
Ida, finished her internship and worked in gastrointestinal and orthopaedic surgery before completing a PhD within the field of osteoarthritis. After having completed the programme Ida has worked in Global Safety prior as a Safety Surveillance Principal Specialist and now as Manager. In addition, Ida was the manager of the PMP programme during 2016.
Florian joined the programme after working with cardiology and nephrology in the clinic and has previously conducted research within neuroanatomy. Following the programme he joined Global Medical Affairs, where he headed up the Liraglutide Diabetes team as a Senior Global Medical Director for a couple of years and then has become Vice President in Global Medical Affairs.
Anders, who prior to joining the programme worked in the clinic, conducted research and completed a PhD within the field of rheumatology. Following the PMP programme Anders has held different positions within Global Development and is now working as a Director in Medical and Science in the GLP-1 and Obesity area.
In 2009, the PMP team included Oscar, Claus and Jeppe.
Oscar worked and researched within cardiovascular medicine before joining the programme. After a couple of years he chose to return to the public health care system.
Claus previously worked in the clinic and conducted research within inflammation and chronic autoimmune diseases. After the program, he joined Global Medical Affairs, where he headed up the area of GLP-1 Obesity as a Global Medical Director. After a couple of years Claus decided to continue his career within a smaller pharmaceutical company.
Jeppe joined the programme after working in the clinic and several years of research within inflammation and cardiovascular disease resulting in a PhD degree. He worked as an International Medical Director within Global Development in one of the key focus areas in Novo Nordisk working on new generation of GLP-1RAs and then has been appointed Senior Director in Medical & Science, Semaglutide Diabetes & Diabetes Outcomes.
The 2008 PMP participants were Charlotte, Britt and Katja.
Charlotte, who prior to the programme worked and researched within obstetrics and gynaecology where she achieved a PhD degree, became an International Medical Director within Global Development in one of the key focus areas in Novo Nordisk working on the new generation of insulins.
Katja, who had previously been engaged in research within the field of Neurology, became a Global Medical Advisor within Global Medical Affairs. After some years in Novo Nordisk, Katja has returned to pursuing a clinical career.
Britt, who before joining Novo Nordisk had started her specialist training as a General Practitioner within the public healthcare system, joined Global Safety as a Safety Surveillance Advisor after finishing the programme. In 2012 she was appointed Team Leader in Safety Surveillance and then has become Principal Specialist.
In 2007 the PMP team included of Marek, Troels and David.
Marek, who previously worked and researched within endocrinology, became an International Medical Director and worked in Global Development, M&S, Insulin & Digital Health for a number of years. Afterwards, he decided to continue his career within another pharmaceutical company.
Troels, who previously worked and researched within the areas of thoracic and abdominal surgery, became a Global Medical Advisor within Medical Affairs. Troels worked the first years within GLP-1 Diabetes and was later promoted to Senior Global Medical Advisor. Troels held a position as the Head of Medical Affairs in Novo Nordisk UK and Ireland for a number of years before returning to headquarters as Senior Global Medical Director within Medical Affairs. Troels is now Vice President in Medical and Scientific Affairs in the European office of Novo Nordisk.
Last but not least David, who had his internship in New York, US, where he also did research focusing on cardiovascular diseases, became an International Medical Director within Global Development and hereafter a Global Medical Advisor. After several years with Novo Nordisk, David has chosen to pursue a career as an endocrinologist and has returned to clinical training.
In 2006 the PMP team included Trine and Yan.
Trine who previously worked within internal medicine moved on to a position as International Medical Director within Global Development and has since been working in key projects of new generation insulin and GLP-1 and obesity respectively.
Yan moved on to a position as Global Medical Advisor within Medical Affairs. After some time she decided to move out of Denmark and is no longer employed with Novo Nordisk.
What is the PMP?
Why did you apply for the PMP?
What was the best thing about the PMP?
How can you use your medical experience?
Do you need a specific medical background?
Is a Ph.d. a requirement?
Why start in the PMP oppose to in one of the 3 areas?
Were you aware of your future tasks before applying?
How do you experience the work/life balance?
Do you miss saving lives at the hospital?
What happens after the PMP?
In order to qualify for the Pharmaceutical Medicine Programme, you must hold a university degree as a medical doctor. You should have passed postgraduate internship and possess 2-5 years of documented scientific and/or clinical experience. You must have practical and analytical skills and be capable of working independently, while at the same time accepting a strong team focus and influence. Moreover, you should be prepared and willing to travel and work in an international arena. We expect that you are results oriented, good at setting priorities and have a strong personal impact and drive. Lastly, we expect you to have excellent English skills and a high proficiency in IT knowledge.
Yes, Novo Nordisk is a global company and welcomes applications from all over the world. It is not a prerequisite that you understand and/or can speak Danish but you must be fluent in English (written and verbal).
The departments included in the programme are all situated at headquarters. That means that you will be working within the Copenhagen area during the 2 years of the Pharmaceutical Medicine Programme. Expatriation is not a part of the programme. After the successful completion of the programme each PMP doctor will be offered a permanent position within headquarters (Denmark). If it is a wish from the PMP doctor and availability enables it, a position in one of Novo Nordisk’s affiliates around the world may be offered.
This would over-qualify the applicant and is neither the scope nor profile we are looking for with this programme. The purpose of the programme is to introduce a medical doctor to the pharma industry and all the facets relevant for a medical doctor working in Novo Nordisk
We are looking for around five MD’s a year. Apply here from February 2019. The programme starts in September 2019.
Work with your competencies within clinical work, scientific research, clinical drug research and business/economy.
The salary is at a competitive level compared to the pharmaceutical industry. It is equal to that of a young medical doctor in an entry level position within the pharmaceutical industry. Along with the salary come additional benefits, for example an annual bonus, computer, mobile phone, re-location aid and an extensive and generous training course budget.
The two-year programme consists of three eight-month rotations in three different areas of the organisation - Global Development, Global Medical Affairs and Global Safety. Within the three departments you will be involved in specific everyday tasks through which you will get experience with elements such as clinical development planning of a drug candidate, global and local positioning strategies for a marketed drug, medical documentation in a new drug application, pharmacovigilance activities such as monitoring adverse events in clinical trials for developmental drugs and making surveys of adverse events for marketed drugs. In addition to the rotations, an individual course plan is created allowing the candidates to participate in internal and external courses. This can for example include training in GCP (good clinical practice), biostatistics, computer skills and participation in congresses.
Yes, it is a permanent position. It is not a scholarship or a grant.
The programme is structured around three main activities within the development of new drugs, where strong medical skills are highly needed.
After/upon successful completion of the programme you will be offered a position usually within one of the three departments in the programme. Your final position depends on your wishes, feedback from managers and vacancies in the respective departments.
Feel free to contact PMP Manager Cecilie Elisabeth Heerdegen Jepsen